The marijuana legalization trend is picking up steam now that Canada has fully legalized cannabis.
And we've got a stock price prediction that marijuana investors can't afford to miss as cannabis goes mainstream.
The cannabis industry is expected to jump from $10 billion in legal sales in 2017 to $24.5 billion by 2021.
That's a 145% sales increase in just four years, and investing in the right cannabis stocks now could provide life-changing returns.
However, we understand that some investors are still hesitant to place their hard-earned money in marijuana stocks...
All cannabis use may be legal for our neighbors in Canada, but it's still illegal under U.S. federal law.
Still, this is a profit opportunity you can't afford to miss...
THREE STOCKS: Any one of these cannabis companies could potentially deliver a 1,000% windfall. Click here to learn more...
We've uncovered a medical marijuana stock that allows risk-averse investors to get in on the $10 billion cannabis market right now.
This biopharmaceutical company has been in business since 1998, and it has the first FDA-approved drug derived from cannabis that could be sold before the end of 2018.
This is the perfect opportunity to profit from the marijuana industry before it becomes completely mainstream...
This Medical Pot Stock Could Provide Double-Digit Returns
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
UK-based pharmaceutical manufacturer GW Pharmaceuticals Plc. (NASDAQ: GWPH) targets the development of marijuana-based experimental drugs for specific conditions.
GW's Epidiolex drug is focused on treatment for two rare forms of epilepsy. Researchers at GW are currently investigating its use for two other conditions that cause seizures.
In late June 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex for patients with Dravet Syndrome and Lennox-Gastaut Syndrome. The approval was the first time the FDA had approved a drug that used a cannabis-derived substance.
Money Morning Defense and Tech Specialist Michael A. Robinson forecasts that Epidiolex could generate revenue of up to $1.7 billion by 2026.
On Nov. 9, the GWPH stock price opened at $146.50 per share.
One analyst from FactSet believes in the next 12 months GWPH will trade for $227 per share, which is a potential 54.94% profit.
These 3 Stocks Are the Key to 2018's Greatest Profits
The 2018 midterm election was a turning point for the cannabis industry.
We expect nothing short of historic profits by the end of the year.
But not all pot stocks will hand you life-changing wins. In fact, often the companies making headlines are least likely to see the biggest gains.
These three stocks, on the other hand, are flying under the radar... for now. Each of them could see exponential stock price acceleration at any moment, and if you get in before that happens, you could turn a token stake into a lifetime of wealth.
I don't know of any other sector providing anywhere near this level of growth now.